RLAY
MaterialsRelay Therapeutics Inc
$12.92-0.08 (-0.62%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RLAY Today?
No stock-specific AI insight has been generated for RLAY yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$2.5B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume3.4M
Avg Volume (10D)—
Shares Outstanding191.3M
RLAY News
20 articles- Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 5, 2026
- Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate UpdatesYahoo Finance·May 5, 2026
- Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways247 Wall St·May 4, 2026
- Relay Therapeutics Advances Zovegalisib To Phase 3 As Valuation Gap PersistsYahoo Finance·May 2, 2026
- Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·Apr 30, 2026
- Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026Yahoo Finance·Apr 29, 2026
- Relay Therapeutics (RLAY) Falls Hard on Profit-Taking From 74% April JumpYahoo Finance·Apr 29, 2026
- Relay Therapeutics Unveils Zovegalisib Triplet Data, Signs Pfizer Supply Deal for Phase III PlanMarketbeat·Apr 28, 2026
- Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast CancerGlobeNewswire Inc.·Apr 27, 2026
- JonesResearch Initiates Coverage of Relay Therapeutics (RLAY) With a Hold RatingYahoo Finance·Apr 20, 2026
- Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?Yahoo Finance·Apr 6, 2026
- Relay Therapeutics (RLAY) Is Up 30.6% After Expanding Zovegalisib Into Vascular Anomalies Data RevealYahoo Finance·Apr 4, 2026
- Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment UpdateYahoo Finance·Apr 3, 2026
- Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026Yahoo Finance·Apr 2, 2026
- Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.Motley Fool·Mar 19, 2026
- Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026Yahoo Finance·Mar 16, 2026
- Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?Yahoo Finance·Mar 11, 2026
- Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor InterestYahoo Finance·Feb 28, 2026
- Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 MillionMotley Fool·Feb 27, 2026
- Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 MillionMotley Fool·Feb 27, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$13.00
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$2.5B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume3.4M
Avg Volume (10D)—
Shares Outstanding191.3M
About Relay Therapeutics Inc
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—